On February 22, 2023, Karin Eastham, a Class III member of the Company's Board, notified the Board of her retirement from Geron Corporation's Board after 13 years of service on the Company's Board and imetelstat's achievement of positive top-line results in the IMerge Phase 3 trial in lower risk myelodysplastic syndromes. As such, she will not stand for re-election at the Company's upcoming 2023 Annual Meeting of Stockholders. Ms. Eastham's decision not to stand for re-election was not due to any disagreement with the Company, the Board or the management of the Company on any matter relating to the Company's operations, policies or practices.

The effective date of departure for Ms. Eastham will be May 31, 2023, the expected date of the Company's 2023 Annual Meeting of Stockholders. Until her departure from the Board, Ms. Eastham will continue to serve on the Audit Committee and the Compensation Committee of the Board, as well as Lead Independent Director for the Board.